Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TELA Bio (TELA) EBITDA (2018 - 2025)

Historic EBITDA for Bio (TELA) over the last 8 years, with Q3 2025 value amounting to -$8.6 million.

  • Bio's EBITDA rose 1662.63% to -$8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.1 million, marking a year-over-year increase of 590.96%. This contributed to the annual value of -$37.8 million for FY2024, which is 1900.78% up from last year.
  • Bio's EBITDA amounted to -$8.6 million in Q3 2025, which was up 1662.63% from -$9.9 million recorded in Q2 2025.
  • In the past 5 years, Bio's EBITDA registered a high of -$5.7 million during Q1 2024, and its lowest value of -$12.9 million during Q4 2023.
  • Moreover, its 5-year median value for EBITDA was -$9.8 million (2022), whereas its average is -$9.6 million.
  • Per our database at Business Quant, Bio's EBITDA skyrocketed by 5309.78% in 2024 and then crashed by 9916.89% in 2025.
  • Bio's EBITDA (Quarter) stood at -$7.7 million in 2021, then dropped by 23.32% to -$9.4 million in 2022, then crashed by 37.03% to -$12.9 million in 2023, then increased by 28.35% to -$9.3 million in 2024, then increased by 7.14% to -$8.6 million in 2025.
  • Its EBITDA stands at -$8.6 million for Q3 2025, versus -$9.9 million for Q2 2025 and -$11.3 million for Q1 2025.